y16

Y16 is a G protein-coupled Rho GEFs inhibitor that synergizes with Rhosin G04 to inhibit LARG-RhoA interaction, RhoA activation, and RhoA-mediated signaling. Y16 is also a specific inhibitor of LARG with a Kd of 76 nM.

Y16 acetate(429653-73-6 free base) is a G-protein–coupled Rho GEFs inhibitor; works synergistically with Rhosin G04 in inhibiting LARG-RhoA interaction, RhoA activation, and RhoA-mediated signaling functions.

WNY1613 is a potent and selective PI3Kδ inhibitor with a piperazinone-containing purine scaffold, exhibiting anti-NHL effects both in vitro and in vivo by inhibiting phosphorylation of downstream components of PI3K in NHL cell lines and inducing apoptosis in cancer cells.

Y16526 is a potent inhibitor of the CBP p300 bromodomain (CBP p300bromodomain) with an IC50 of 0.03 μM. Y16524 shows potential for research in acute myeloid leukemia (AML).

Y16524 is a potent inhibitor of the CBP p300 bromodomain (CBP p300bromodomain) with an IC50 value of 0.01 μM. It shows potential for research in acute myeloid leukemia (AML).